Dr. Eskelund Discusses TP53 Mutated Mantle Cell Lymphoma

Christian Winther Eskelund, MD
Published: Wednesday, Jun 28, 2017



Christian Winther Eskelund, MD, Copenhagen University Hospital, Rigshospitalet, discusses TP53-mutated mantle cell lymphoma (MCL).

TP53 has been associated with poor outcomes in many different cohorts of MCL, says Eskelund.

Eskelund suggests that TP53 status should be measured upfront in patients who are diagnosed with MCL. As clinical trials become available, treating physicians should highly consider entering their patients onto them.
 
SELECTED
LANGUAGE


Christian Winther Eskelund, MD, Copenhagen University Hospital, Rigshospitalet, discusses TP53-mutated mantle cell lymphoma (MCL).

TP53 has been associated with poor outcomes in many different cohorts of MCL, says Eskelund.

Eskelund suggests that TP53 status should be measured upfront in patients who are diagnosed with MCL. As clinical trials become available, treating physicians should highly consider entering their patients onto them.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x